Never Ignore Endotoxin Test Failures in WFI Systems

Don’t Ignore Endotoxin Test Failures in Water for Injection (WFI) Systems

Remember: Never disregard endotoxin test failures in WFI systems — they indicate serious contamination risks that demand immediate investigation and corrective action.

Why This Matters in GMP

Water for Injection (WFI) is used in the manufacture of sterile products, rinsing of product contact parts, and dilution of injectable solutions. It must meet stringent microbiological and endotoxin limits. Endotoxins — toxic components of Gram-negative bacterial cell walls — can cause fever, shock, or even death if injected. A failed endotoxin test signals that the WFI system may be harboring bacterial growth, posing a direct threat to product safety.

Also Read: Don’t Adjust Sampling Volumes Without Documented GMP Justification

For example, if an endotoxin level above 0.25 EU/mL is detected in routine sampling, and the result is ignored or not investigated, WFI used in batch manufacturing may introduce pyrogenic contaminants into the drug product. This not only risks patient harm but can also lead to recalls, regulatory actions, and facility shutdowns.

Regulatory and Compliance Implications

21 CFR Part 211.67 and Part 211.113 mandate contamination control and require prompt investigation of microbial failures. EU GMP Annex 1 and WHO GMP stress that all critical utility systems, including WFI, must

be monitored, qualified, and maintained within endotoxin limits. Endotoxin test failures must trigger documented investigations, risk assessments, and system review.

Also Read: Prevent Condensation Build-Up in Sterile Areas to Maintain GMP Integrity

Inspectors will review BET (bacterial endotoxin test) logs, deviation reports, and system cleaning history. Failing to act on a confirmed test failure can lead to serious citations under inadequate system control, batch integrity, and failure to prevent contamination.

Implementation Best Practices

Perform BET testing as per pharmacopoeial methods (e.g., USP or EP 2.6.14) at defined sampling points and frequencies. Use endotoxin-free sampling tools and containers. In case of a failure, initiate a deviation and block affected batches. Conduct root cause investigations into biofilm presence, system design, cleaning frequency, or sanitizer efficacy.

Trend endotoxin results over time and include alert/action levels in monitoring SOPs. Train operators and QA staff in handling test failures, sample integrity, and retesting criteria. Ensure preventive maintenance and sanitization cycles are performed on schedule and verified.

Also Read: Never Initiate CAPA Without Assigning Clear Responsibilities

Regulatory References

– 21 CFR Part 211.113 – Microbiological control in sterile processes
– EU GMP Annex 1 – Water system monitoring and testing
– WHO TRS 970, Annex 3 – GMP for pharmaceutical water
– USP – Bacterial Endotoxin Test (BET)